💪Retatrutide Shows 30% Weight Loss in Late-Stage Trial
Obesity Drug Retatrutide Could Be Game-Changer
TL;DR
Late-stage trial data shows Retatrutide, an obesity drug from Eli Lilly, helped participants lose up to 30% of their body weight after 104 weeks. The drug also improved knee pain and sleep apnea symptoms.
Researchers published late-stage clinical trial data for Retatrutide, an obesity drug from Eli Lilly, showing participants lost up to 30% of their body weight after 104 weeks. This could be a game-changer for those struggling with obesity, as it also improved knee pain and sleep apnea symptoms. The trial included 2,339 participants from 131 sites in 11 countries, with the highest dose group losing 25% of their body weight after 80 weeks. The drug targets GLP-1, GIP, and glucagon, making it more effective than existing treatments.
Key Points
Retatrutide trial included 2,339 participants from 131 sites in 11 countries.
Participants lost up to 30% of their body weight after 104 weeks on the highest dose.
The drug reduced knee pain by up to 62% in participants with knee osteoarthritis.
Retatrutide reduced sleep apnea events by up to 57% in participants with sleep apnea.
The drug improved cardiometabolic measurements across the board.
Why It Matters
If you're dealing with obesity, Retatrutide could be a game-changer. Participants lost up to 30% of their body weight after 104 weeks, with significant improvements in knee pain and sleep apnea. The drug's multi-hormone approach makes it more effective than existing treatments.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,567 builders reading daily.